THAR

Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. It has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.

Wall Street analysts forecast THAR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for THAR is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Tharimmune Inc revenue for the last quarter amounts to -2.09M USD, decreased -45.84 % YoY.

Tharimmune Inc. EPS for the last quarter amounts to USD, decreased % YoY.

Tharimmune Inc (THAR) has 2 emplpoyees as of December 15 2025.

Today THAR has the market capitalization of 83.76M USD.